These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
197 related items for PubMed ID: 7203726
1. Pharmacokinetics and metabolism of theophylline in patients with liver diseases. Staib AH, Schuppan D, Lissner R, Zilly W, von Bomhard G, Richter E. Int J Clin Pharmacol Ther Toxicol; 1980 Nov; 18(11):500-2. PubMed ID: 7203726 [Abstract] [Full Text] [Related]
2. [Drug metabolism in patients with liver disease (author's transl)]. Richter E, Epping J, Fuchshofen-Röckel M, Heusler H, Zilly W. Leber Magen Darm; 1980 Oct; 10(5):234-40. PubMed ID: 7464410 [Abstract] [Full Text] [Related]
3. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. Orlando R, Padrini R, Perazzi M, De Martin S, Piccoli P, Palatini P. Clin Pharmacol Ther; 2006 May; 79(5):489-99. PubMed ID: 16678550 [Abstract] [Full Text] [Related]
4. [Clinico-prognostic significance of plasma cortisol half-life(after intravenous administration ) during acute and chronic hepatic diseases]. Del Prete S, Malacco E, Bonzi G, Natelli A, Roncoroni S, Jalanbo H. Minerva Med; 1975 Mar 24; 66(22):1051-7. PubMed ID: 1124151 [Abstract] [Full Text] [Related]
5. [Anti-rheumatic therapy in patients with liver diseases. Plasma levels of diclofenac and elimination of diclofenac and metabolites in urine of patients with liver disease]. Zimmerer J, Tittor W, Degen P. Fortschr Med; 1982 Sep 23; 100(36):1683-8. PubMed ID: 7141370 [Abstract] [Full Text] [Related]
6. Enhanced renal clearance of uric acid in hepatic cirrhosis. Higuchi T, Nakamura T, Uchino H. Isr J Med Sci; 1981 Nov 23; 17(11):1015-8. PubMed ID: 7319788 [Abstract] [Full Text] [Related]
7. [Metabolism of hexobarbital in patients with acute hepatitis and cirrhosis (author's transl)]. Richter E, Gallenkamp H, Keller B, Brachtel D, Zilly W, Breimer DD. Z Gastroenterol; 1977 Jun 23; 15(6):381-8. PubMed ID: 888488 [Abstract] [Full Text] [Related]
8. Drug disposition in liver disease. Fruncillo RJ. Am Fam Physician; 1982 Dec 23; 26(6):167-9. PubMed ID: 7148640 [No Abstract] [Full Text] [Related]
9. [Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases]. Ohnhaus EE, Münch U, Meier J. Schweiz Med Wochenschr; 1976 Dec 04; 106(49):1748-50. PubMed ID: 1013699 [Abstract] [Full Text] [Related]
10. Pharmacokinetics of trapidil (Rocornal) in patients with chronic liver disease. Berndt A, Pönicke K, Weiss M. Int J Clin Pharmacol Ther Toxicol; 1992 Nov 04; 30(11):492-3. PubMed ID: 1490801 [Abstract] [Full Text] [Related]
11. Influence of hepatic insufficiency in pharmacokinetics of drugs: example for an anthranilic diuretic. Dreux C, Passa P, Halter D. Methods Find Exp Clin Pharmacol; 1979 Dec 04; 1(5):289-96. PubMed ID: 552592 [Abstract] [Full Text] [Related]
12. Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism. Jennings TS, Nafziger AN, Davidson L, Bertino JS. J Lab Clin Med; 1993 Aug 04; 122(2):208-16. PubMed ID: 8340707 [Abstract] [Full Text] [Related]
13. Altered kinetics of etozolin and its active metabolite ozolinone in hepatitis and hepatic cirrhosis with ascites. Knauf H, Missmahl M, Schölmerich J, Gerok W, Mutschler E. Arzneimittelforschung; 1987 Dec 04; 37(12):1385-8. PubMed ID: 3449068 [Abstract] [Full Text] [Related]
14. Biotransformation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis - evidence for active benzbromarone metabolites? Walter-Sack I, de Vries JX, von Bubnoff A, Pfleilschifter V, Raedsch R. Eur J Med Res; 1995 Oct 16; 1(1):16-20. PubMed ID: 9392688 [Abstract] [Full Text] [Related]
15. [Peculiarities of the pharmacokinetics and pharmacodynamics of theophylline in children]. Berdel D, Heimann G. Wien Klin Wochenschr; 1984 Aug 31; 96(16):616-21. PubMed ID: 6516414 [Abstract] [Full Text] [Related]
16. [Metabolism of phenylbutazone in the liver (author's transl)]. González Macías J, De Castro del Pozo S. Med Klin; 1976 Sep 03; 71(36):1434-8. PubMed ID: 958107 [Abstract] [Full Text] [Related]
17. Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium). Roberts RK, Wilkinson GR, Branch RA, Schenker S. Gastroenterology; 1978 Sep 03; 75(3):479-85. PubMed ID: 680505 [Abstract] [Full Text] [Related]
18. Half-life time or clearance of indocyanine green in patients with liver disease. Gilmore IT, Marigold JH, Thompson RP. Hepatogastroenterology; 1982 Apr 03; 29(2):55-7. PubMed ID: 7084884 [Abstract] [Full Text] [Related]
19. Metabolism of a prednisolone compound in human under normal and pathological conditions. Fehér T, Koref O, Tankó A, Bodrogi L, Poteczin E. Arzneimittelforschung; 1975 Aug 03; 25(8):1314-7. PubMed ID: 52365 [Abstract] [Full Text] [Related]
20. Caffeine clearance by two point analysis: a measure of liver function in chronic liver disease. Wittayalertpanya S, Israsena S, Thamaree S, Tongnopnoua P, Komolmit P. Tokai J Exp Clin Med; 1996 Dec 03; 21(4-6):195-201. PubMed ID: 9300980 [Abstract] [Full Text] [Related] Page: [Next] [New Search]